Table 2.
Cohort 2: University of Arizona and Arizona Donor Network: COPD patients and controls
| N | NS | Smokers | COPD | P | |
|---|---|---|---|---|---|
| Total participants (N) | 47 | 10 | 16 | 21 | |
| Age | 47 | 56 ± 18*a | 67 ± 6 | 66 ± 9 | P < 0.01a |
| Gender (M/F) | 47 | 7/3 | 7/9 | 12/9 | NS |
| Smoking history (pack years) | 47 | 0 | 33 ± 15*** | 38 ± 21*** | P < 0.001 |
| Smoking habit (current/former smoker) | 47 | 0 | 6/10 | 5/16 | NS |
| Spirometry | 43 | 7 | 16 | 20 | |
| FEV1 (% predicted) | 43 | 77 ± 16 | 88 ± 21 | 40 ± 24***^ | P < 0.001 |
| FEV1/FVC | 43 | 82 ± 7 | 80 ± 9 | 41 ± 18***^ | P < 0.001 |
| Comorbidities | 47 | 10 | 16 | 21 | |
| Hypertension N (%) | 47 | 5 (50%) | 9 (56%) | 11 (52%) | NS |
| Other cardiovascluar diseases N (%) | 47 | 1 (10%) | 5 (31%) | 5 (24%) | NS |
| Diabetes mellitus N (%) | 47 | 2 (20%) | 2 (13%) | 4 (19%) | NS |
| Medications | 45 | 8 | 16 | 21 | |
| Inhaled corticosteroids N (%) | 45 | 0 | 4 (25%) | 10 (48%)§ | P < 0.05 |
| LABA/SABA/LAMA N (%) | 45 | 0 | 6 (38%) § | 17 (81%)***# | P < 0.01 |
| Oral corticosteroids N (%) | 45 | 1 (13%) | 0 | 3 (14%) | NS |
| ACEi/ARB N (%) | 45 | 3 (38%) | 4 (44%) | 9 (43%) | NS |
| Ca Antagonists/B-blockers N (%) | 45 | 2 (25%) | 6 (38%) | 6 (29%) | NS |
| Diuretics N (%) | 45 | 2 (25%) | 5 (31%) | 2 (10%) | NS |
Data are mean ± SD, unless specified
NS never-smokers
*P < 0.01 versus Smokers and COPD patients; §P < 0.05 compared to NS; °P < 0.001 compared to smokers and NS; ***P < 0.001 compared to NS; #P < 0.01 compared to NS. ^P < 0.001 compared to smokers
aDue to the significant difference in age between NS versus COPD and Smokers, ACE2 levels were corrected for age using linear regression models